NIH Licenses New Antibody to Spot Immune Cell Proteins
Published Date: 6/1/2026
Notice
Summary
The National Institutes of Health just announced a cool new antibody called 18H2 that helps scientists spot a key protein in immune cells that keep us healthy. This invention is ready for companies to license and turn into real products, speeding up research and treatments for autoimmune diseases. If you’re interested, now’s the time to reach out and get the details—money and timing depend on your licensing deal!
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Antibody 18H2 Available For Licensing
The NIH/NIAID has made monoclonal antibody 18H2 (HHS Ref. No. E-104-2025-0) available for licensing for commercial development under 35 U.S.C. 209 and 37 CFR part 404. If you are a company or research group, you can contact Yogikala Prabhu (tel. 202-365-4785 or [email protected]) to inquire about licensing.
Collaborative Research Opportunities Offered
NIAID is actively seeking statements of capability or interest for collaborative research to further develop, evaluate, or commercialize 18H2, including use in pre-clinical models, diagnostic assay development, and high-throughput screening. Interested parties should contact Yogikala Prabhu at 202-365-4785 or [email protected].
Enables Development of Diagnostic Tests
The 18H2 antibody can be used to develop tests that track regulatory T cell (Treg) function and Eos protein levels in patients to monitor autoimmune diseases, cancer treatments, and organ transplants. Companies and labs could use this technology to build diagnostic assays and immune-monitoring tools.
Technology Is at Pre-Clinical Stage
The 18H2 antibody is described as being at the 'Pre-Clinical' development stage. That means the technology has been validated in laboratory settings but has not yet reached clinical trials or market-ready status.
Confidential Disclosure Agreement Required
A signed Confidential Disclosure Agreement (CDA) is required to receive copies of unpublished information related to the 18H2 invention. Parties must sign the CDA before NIH/NIAID will provide unpublished technical details.
Foreign Patent Filings May Extend Coverage
The notice states that foreign patent applications are filed on selected inventions to extend market coverage and may also be available for licensing. This can affect the geographic scope of licensing rights for 18H2.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-10811, National Eye Institute; Notice of Closed Meeting
The National Eye Institute’s advisory council is holding a private virtual meeting on July 17, 2026, to review and decide on grant applications. This meeting affects researchers seeking funding for eye-related projects and keeps sensitive info safe. No money changes are announced yet, but the decisions could impact future research support.
Next: 2026-10814, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.